Evidence map›Paper›PMID 28754892›Full record

ArticleScientific reports2017

A cell-based high-throughput screening assay system for inhibitor compounds of antigen presentation by HLA class II molecule.

Nobuo Watanabe, Yusuke Suzuki, Takahisa Yonezu, Yuki Nakagawa, Takashi Shiina, Noriaki Hirayama, Sadaki Inokuchi, Shigeaki Inoue

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Nobuo WatanabeDepartment of Emergency and Critical Care Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan.
Yusuke SuzukiDepartment of Emergency and Critical Care Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan.
Takahisa YonezuDepartment of Emergency and Critical Care Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan.
Yuki NakagawaDepartment of Emergency and Critical Care Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan.
Takashi ShiinaDepartment of Molecular Life Science, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan.
Noriaki HirayamaInstitute of Advanced Biosciences, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan.
Sadaki InokuchiDepartment of Emergency and Critical Care Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan.
Shigeaki InoueDepartment of Emergency and Critical Care Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan. sg-inoue@is.icc.u-tokai.ac.jp.
Tokai University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A number of autoimmune diseases are associated with the genotypes of human leukocyte antigen class II (HLA), some of which present peptides derived from self-proteins, resulting in clonal expansion of self-reactive T cells. Therefore, selective inhibition of self-peptide loading onto such disease-associated HLA could ameliorate the diseases. To effectively identify such compounds, in this study, we established, for the first time, a cell- and 96-well microplate-based high-throughput screening system for inhibitors of antigen presentation. A panel of DRB1 genes plus DRA*01:01 gene were expressed in HEK293T cells and in 3T3 cells, and their binding with biotinylated known self-antigen peptides was measured by flow cytometry. HLA-DR1 (DRB1*01:01) and DR15 (DRB1*15:01) showed a high affinity with myelin basic protein peptide (MBP83-98). Therefore, in 96-well plate wells, MBP83-99 was allowed to bind to DR1 or DR15 on 3T3 cells in competition with a test compound, and the HLA-bound peptide was detected by streptavidin-conjugated β-galactosidase, thereby identifying inhibitor compounds for rheumatoid arthritis or multiple sclerosis. Our assay system has a potential for broad applications, including designing peptide vaccines.

Indexed as

3T3 CellsAnimalsAntigen PresentationAutoantigensHEK293 CellsHigh-Throughput Screening AssaysHLA-DRB1 ChainsHumansMiceMyelin Basic ProteinPeptidesAutoantigensHLA-DRB1 ChainsMyelin Basic ProteinPeptides

Identifiers

PMID28754892
PMCPMC5533769
OpenAlexW2738499806

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.